354,025 Immunocore Holdings PLC Sponsored ADR $IMCR Shares Sold by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP reduced its position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 75.3% in the third quarter, HoldingsChannel reports. The institutional investor owned 116,000 shares of the company’s stock after selling 354,025 shares during the quarter. Fulcrum Asset Management LLP’s holdings in Immunocore were worth $3,579,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Alps Advisors Inc. boosted its position in Immunocore by 32.7% during the 3rd quarter. Alps Advisors Inc. now owns 68,246 shares of the company’s stock valued at $2,067,000 after buying an additional 16,826 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in Immunocore in the 3rd quarter worth $72,000. China Universal Asset Management Co. Ltd. increased its position in shares of Immunocore by 27.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,252 shares of the company’s stock valued at $285,000 after acquiring an additional 1,975 shares during the period. Crossmark Global Holdings Inc. increased its position in shares of Immunocore by 13.7% in the third quarter. Crossmark Global Holdings Inc. now owns 41,387 shares of the company’s stock valued at $1,254,000 after acquiring an additional 4,971 shares during the period. Finally, Juncture Wealth Strategies LLC purchased a new position in shares of Immunocore in the third quarter valued at about $207,000. 84.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on IMCR. JPMorgan Chase & Co. assumed coverage on shares of Immunocore in a research note on Friday, August 21st. They set an “overweight” rating and a $50.00 price objective for the company. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Morgan Stanley set a $43.00 price target on Immunocore in a report on Friday, August 7th. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Immunocore in a report on Monday, October 26th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $55.86.

Immunocore Price Performance

IMCR stock opened at $31.73 on Tuesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.47 and a quick ratio of 4.44. Immunocore Holdings PLC Sponsored ADR has a 1 year low of $27.50 and a 1 year high of $40.71. The firm has a 50-day moving average of $31.54 and a 200 day moving average of $31.71. The company has a market cap of $1.63 billion, a P/E ratio of -48.81 and a beta of 0.82.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.10). Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%. The firm had revenue of $102.22 million for the quarter, compared to the consensus estimate of $152.49 million. On average, sell-side analysts forecast that Immunocore Holdings PLC Sponsored ADR will post 0.02 EPS for the current year.

Immunocore Company Profile

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach.

The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.